Get the Stockscreener App
3.08
13.65%
0.37
Pre-market:
3.26
0.18
+5.84%
Vistagen Therapeutics Inc stock is traded at $3.08, with a volume of 1.17M.
It is up +13.65% in the last 24 hours and up +51.72% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$2.71
Open:
$2.74
24h Volume:
1.17M
Relative Volume:
5.29
Market Cap:
$89.81M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.2946
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+20.78%
1M Performance:
+51.72%
6M Performance:
+4.41%
1Y Performance:
-15.38%
1-Day Range:
$2.66
$3.24
1-Week Range:
$2.50
$3.24
52-Week Range:
$1.90
$3.79
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.08 | 79.02M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Explosive earnings growth - jammulinksnews.com
What makes Vistagen Therapeutics Inc. stock price move sharplyMaximize returns with data-driven strategies - jammulinksnews.com
When is Vistagen Therapeutics Inc. stock expected to show significant growthDiscover stocks with superior performance - jammulinksnews.com
How volatile is Vistagen Therapeutics Inc. stock compared to the marketBuild wealth steadily with proven methods - jammulinksnews.com
What is the risk reward ratio of investing in Vistagen Therapeutics Inc. stockCapitalize on fast-moving stock opportunities - jammulinksnews.com
Is it the right time to buy Vistagen Therapeutics Inc. stockGet professional advice for portfolio optimization - jammulinksnews.com
Is Vistagen Therapeutics Inc. a growth stock or a value stockExtraordinary performance - jammulinksnews.com
Is Vistagen Therapeutics Inc. stock a good hedge against inflationFree Expert-Led Investment Training - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionPredictable Return Stock Picks - Newser
What makes Vistagen Therapeutics Inc. stock attractive to long term investors200 Percent Watchlist - Newser
Vistagen Therapeutics Inc. Stock Analysis and ForecastSky-high return potential - PrintWeekIndia
Does Vistagen Therapeutics Inc. stock pay reliable dividendsBreakneck growth rates - jammulinksnews.com
Vistagen Showcases Revolutionary Nose-to-Brain Drug Platform: CEO Fireside Chat at BTIG Conference - Stock Titan
What analysts say about Vistagen Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional
Is Vistagen Therapeutics Inc. a good long term investmentTremendous financial leverage - jammulinksnews.com
What drives Vistagen Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat
How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser
Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):